Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen
about
Ovarian carcinoma subtypes are different diseases: implications for biomarker studiesEpigenetic control of the basal-like gene expression profile via Interleukin-6 in breast cancer cellsThe combined status of ATM and p53 link tumor development with therapeutic responseDifferential regulation of human thymosin beta 15 isoforms by transforming growth factor beta 1IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary glandThe rebel angel: mutant p53 as the driving oncogene in breast cancer.p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.NFAT3 transcription factor inhibits breast cancer cell motility by targeting the Lipocalin 2 geneEfficacy of neoadjuvant Cisplatin in triple-negative breast cancerAnnexin/S100A Protein Family Regulation through p14ARF-p53 Activation: A Role in Cell Survival and Predicting Treatment Outcomes in Breast CancerCHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancerReversible p53 inhibition prevents cisplatin ototoxicity without blocking chemotherapeutic efficacyBRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations.The Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set.Changes in allelic imbalances in locally advanced breast cancers after chemotherapy.Should we abandon the t-test in the analysis of gene expression microarray data: a comparison of variance modeling strategiesClinical outcomes and correlates of TP53 mutations and cancer.Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapySmall molecule inhibitor of the RPA70 N-terminal protein interaction domain discovered using in silico and in vitro methods.TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype.Breast cancer genomes--form and functionTP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.Value of TP53 status for predicting response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.The p53 inducing drug dosage may determine quiescence or senescence.Spontaneous abrogation of the G₂DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients.Topo2α protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer.Characterization of the p53 cistrome--DNA binding cooperativity dissects p53's tumor suppressor functions.p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients.TP53 status and response to treatment in breast cancersInhibition of p53 by adenovirus type 12 E1B-55K deregulates cell cycle control and sensitizes tumor cells to genotoxic agentsCaspase-2 impacts lung tumorigenesis and chemotherapy response in vivo.Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.Treatment-induced cell cycle kinetics dictate tumor response to chemotherapyA refined molecular taxonomy of breast cancer.Low expression of stathmin in tumor predicts high response to neoadjuvant chemotherapy with docetaxel-containing regimens in locally advanced breast cancer.TP53 mutation, epithelial-mesenchymal transition, and stemlike features in breast cancer subtypesPrognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.Clinical next generation sequencing to identify actionable aberrations in a phase I program.Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathwayThe association between the T309G polymorphism of the MDM2 gene and sensitivity to anticancer drug is dependent on the p53 mutational status in cellular models.
P2860
Q21563402-94404FD4-2967-484E-B37D-D32604515411Q24629061-AC639679-C1FC-4AF9-8249-D9375716357CQ24652535-0DDA07E4-09D5-45AC-B1CD-B7EA18232C47Q24657893-3B057A43-484D-4693-B4EF-BDBA96FB5DF2Q24669531-00CF6A6D-CAD3-4365-8792-60B15F975DF2Q27686765-6DA25ECA-76A4-468F-BD12-5C6F440C3DFCQ27851827-CF99313E-4310-48DA-B8C0-084388EF696AQ28271428-4D57D688-93A8-47AE-9794-79F1F011A3B1Q28372484-C3358B56-C363-4204-9835-3DE7BC7C7BD9Q28468360-03F3C524-093C-4D4E-9415-1061BB603480Q28473504-1F32D951-0EE0-4743-8BB6-51FCD1645893Q30366115-79FEBA7C-9E75-42EE-BDF8-9A707CF547DBQ30497664-AC75D4AF-A32A-4693-AC6B-5499F505E134Q30978083-31D774BB-A04C-47F8-8502-87362C02F014Q33299319-1F1D0518-B4D6-4340-9741-B2E7F4F13E17Q33691313-37B02C75-7F9C-456F-ABFB-7FA84940164EQ33693838-32EFA12C-3D05-4076-919A-B6F5AC7B7462Q33827045-4F5909AE-D21F-4CBC-AB67-09B0718C8C8DQ33860865-E3238239-80B0-45CE-BA7B-5BFEA403F336Q34130168-F6AFDFEC-530A-4CD4-8ED2-69A8A8C839BBQ34207688-699BED2F-D618-45AF-81C0-15D47BA4B561Q34234217-23DD1F88-1721-403F-9082-B84FCF8F8A58Q34328227-00A88D34-44DA-46DB-8FF1-D559F3FA2B17Q34424866-89AB8514-6DE9-455E-B614-C092ABBAC828Q34428974-14BE511B-E037-41BB-8E9C-085E0508950BQ34433737-636FE999-9018-4AB8-9CB5-F303B1F46BCCQ34961997-9FFD933B-DAA1-4F96-AAD6-292CADF656A5Q35029530-0D5D56C4-FE77-4AEF-BB8C-E2F10BF85B9CQ35043933-A4AC4DDC-6F7A-4633-9BFB-E8FC49F599B2Q35140413-F88F7D48-1BFB-4D11-8936-1247EC6DEC55Q35349417-DE340883-5B74-4B53-8A59-F710CC21499AQ35583968-02FC9474-7634-4D0D-B5F0-9DDDF4EE16BBQ35740145-EE4F68D7-D7DF-453B-9129-1E92EA140F69Q35838290-473A3501-E067-4375-8B7E-2ECA401A1CCAQ36092750-AD1D6642-C5AF-47E6-826F-B5198AC5CD27Q36148592-3AD0DB65-36A8-41DB-9BD1-E2A98A08B56EQ36245341-CEC3CBC7-1A5B-49F2-B18B-10DF8B24E399Q36299589-8750AA69-99F0-485A-BD65-63DCEF9FC704Q36385696-5EDF091A-359F-451D-B154-2D98F1E3B042Q37287418-E8BAD543-F8DE-4EFA-A8BF-5E2E17E4F444
P2860
Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Exquisite sensitivity of TP53 ...... bicin-cyclophosphamide regimen
@ast
Exquisite sensitivity of TP53 ...... bicin-cyclophosphamide regimen
@en
Exquisite sensitivity of TP53 ...... bicin-cyclophosphamide regimen
@en-gb
Exquisite sensitivity of TP53 ...... bicin-cyclophosphamide regimen
@nl
type
label
Exquisite sensitivity of TP53 ...... bicin-cyclophosphamide regimen
@ast
Exquisite sensitivity of TP53 ...... bicin-cyclophosphamide regimen
@en
Exquisite sensitivity of TP53 ...... bicin-cyclophosphamide regimen
@en-gb
Exquisite sensitivity of TP53 ...... bicin-cyclophosphamide regimen
@nl
altLabel
Exquisite Sensitivity of TP53 ...... bicin−Cyclophosphamide Regimen
@en
prefLabel
Exquisite sensitivity of TP53 ...... bicin-cyclophosphamide regimen
@ast
Exquisite sensitivity of TP53 ...... bicin-cyclophosphamide regimen
@en
Exquisite sensitivity of TP53 ...... bicin-cyclophosphamide regimen
@en-gb
Exquisite sensitivity of TP53 ...... bicin-cyclophosphamide regimen
@nl
P2093
P2860
P50
P3181
P1433
P1476
Exquisite sensitivity of TP53 ...... bicin-cyclophosphamide regimen
@en
P2093
Anne Janin
Anne de Roquancourt
David S Rickman
Elisabeth Turpin
Hany Soliman
Jean-Louis Misset
Jean-Paul Feugeas
Louis-François Plassa
Marc Espié
Mariana Varna
P2860
P3181
P356
10.1371/JOURNAL.PMED.0040090
P407
P577
2007-03-01T00:00:00Z